v3.26.1
Condensed Consolidated Statements of Changes in Cash Flows Unaudited - USD ($)
 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Operating activities    
Net income (loss) $ (3,694,415) $ 2,398,248
Adjustments for non-cash items in net income (loss) and earnings impact of warrant liability reclassification:    
Depreciation of property and equipment 156,812 212,911
Depreciation of property and equipment included in costs of finished cannabis inventory sold 1,577,038 795,337
Lease costs included in costs of finished cannabis inventory sold 542,497 927,805
Share-based compensation 304,081 1,772,735
Interest and accretion expense 979,220 690,724
Other income (5,251)
Interest income (84,844) (72,274)
Unrealized (gain) loss on derivative liability (148,383) 27,654
Realized (gain) loss on derivative liability (5,859,744)
Unrealized loss on warrant asset 2,747,667 1,340,654
Unrealized gain on warrant liability (433,547)
Loss on equity investment in associate 293,250 268,420
Deferred income taxes (272,243) (55,184)
Changes in operating assets and liabilities (Note 18) 2,280,732 (3,098,916)
Net cash provided by (used in) operating activities 4,247,865 (656,881)
Investing activities    
Purchase of property and equipment (5,498,773) (241,532)
Payments of business acquisition consideration payable (377,988) (254,828)
Investment in Rogue EBC, LLC equity interest (415,000) (468,000)
Net cash used in investing activities (6,291,761) (964,360)
Financing activities    
Sale of non-controlling interest in GRMA, net of issuance costs 2,985,000
Proceeds from exercise of stock options 21,839 402,844
Proceeds from long-term debt 1,000,000 7,471,063
Distributions to non-controlling interests in subsidiaries (235,156) (70,000)
Debt issuance costs (246,913)
Repayment of long-term debt (1,529,295) (1,169,064)
Payment of interest on convertible debentures (79,755)
Repayment of finance lease (37,500) (6,250)
Net cash provided by financing activities 2,204,888 6,301,925
Effect of foreign exchange on cash and cash equivalents 1,285
Change in cash and cash equivalents 160,992 4,681,969
Cash and cash equivalents, beginning of period 11,371,834 4,917,708
Cash and cash equivalents, end of period $ 11,532,826 $ 9,599,677